Committed to medical innovation

Since 2007, we at Endor conduct medical research in the areas of oncology and skin care. Our main goal is improving people´s health through the development of innovative treatments based on medical research.

Endor Technologies

Endor Technologies was established in 2007 as an spin-off of the “Instituto Catalán de Nanotecnología”. Over the last decade, in addition to research projects, our research has resulted in patents, doctoral thesis, publications, books, congress and international awards. Endor is a proud member of the SME programme of the European Medicine Agency and has the status of a innovative company granted by the Spanish Ministerio de Economía y Competitividad:


Biotechnological product of the year

European Biotechnology Congress 2016: "Cancer treatment through the use of immunostimulating proteins ".

Award to the best innovative company in 2014.

Universidad de Barcelona.

Innovative company

Recognition granted by The Spanish Ministerio de Economía y Competitividad.

Status of SME in the EMA

(European Medicines Agency).


"Proteins for use in cancer treatment".

Querol Sastre J., Sobrevals L., Parkkola H., Vivero L., Miñana R., Sendra J. Application Number: 15179043.3-1456. Applicant: Endor Technologies S.L.

"System for the release of a therapeutic agent, pharmaceutical composition containing it, the preparation and medical use thereof".

Querol Sastre J., Sendra Cuadal J., Vivero Sanchez L., Ramis Castelltort M., Parkkola H. International Publication Number WO 2012/089768-A1. Applicant: Endor Technologies, S.L.

"Conjugate of Hyaluronic Acid for Cosmetic Treatment and Preparation Method".

Querol Sastre J., Ramis Castelltort M., Ojea Jimenez I. International Publication Number: WO 2009/087254-A1 Applicant: Endor Technologies S.L.

"Metal nanoobjects for cosmetic use".

Querol Sastre J., Escudero Cano J. International Publication Number: EP18382052.1 Applicant: Endor Technologies S.L.


"Nanosistemas avanzados basados en nanopartículas de oro y ácido hialurónico para aplicaciones dermatológicas y cosméticas".

Autor: Rafael Miñana Prieto.
Directora: Judith Sendra PhD.

"Hyaluronic acid-coated gold nanoparticles as an anticancer drug delivery system - Biological characterization and efficacy".

Author: Hanna Parkkola.
Director: Judith Sendra PhD.

"Diseño y caracterización de sistemas de liberación de fármacos basados en nanopartículas metálicas y ácido hialurónico".

Author: Laura Vivero Sanchez.
Directora: Judith Sendra PhD.


"Nanotechnology: Recent Trends, Emerging Issues and Future Directions. Chapter: Nanomedicine: The New Age of Therapeutics".

Sobrevals L., Parkkola H., Vivero L., Miñana R., Sendra J., 2014. Editor: N. Nova Science Publishers, Inc.

"Converging hazard assessment of gold nanoparticles to aquatic organisms”.

Jesús Pablo García-Cambero, Mercedes Núñez García, Gema Díaz López, Ana López Herranz, Laureano Cuevas, Esperanza Pérez-Pastrana, Judith Sendra Cuadal, Marc Ramis Castelltort, Argelia CastYear Calvo. Chemosphere 93 (2013). 1194-1200.

"Proceed with caution? Concept and application of the precautionary principle in nanobiotechnology: Gold Nanoparticles and Cell Viability Evaluation".

Parkkola H., Vivero L., Ramis M., Querol J., Sendra J., 2012. Editors: Ach J.S., Lüttenberg B., Paslack R., Weltring K-M. LIT Verlag.

"Gold Nanoparticle Stability Studies in Physiological Media".

Parkkola H., Vivero L., Ramis M., Cambero J.P.G., Querol J., Sendra J., 2012. Editors: Ach J.S., Lüttenberg B., Paslack R., Weltring K-M. LIT Verlag.

"In Vitro Safety Toxicology Data for Evaluation of Gold Nanoparticles–Chronic Cytotoxicity, Genotoxicity and Uptake".

Claudia Di Guglielmo, Joaquín De Lapuente, Constança Porredon, David Ramos-López, Judith Sendra, and Miquel Borràs. Journal of Nanoscience and Nanotechnology. Vol. 12, 6185-6191, 2012.

"Embryotoxicity of cobalt ferrite and gold nanoparticles: A first in vitro approach".

Claudia Di Guglielmoa, David Ramos Lópeza, Joaquín De Lapuente, Joan Maria Llobet Mallafre, Miquel Borràs Suàreza. Reproductive Toxicology 30 (2010) 271-276.

"Metallic Nanoparticles and Cytotoxicity Assessment".

Parkkola H., Vivero L., Vega M., Ramis M., Querol Sastre J., Sendra J., 2010. International Congress of Toxicology.

"Instability of Cationic Gold Nanoparticle Bioconjugates: The Role of Citrate Ions".

Isaac Ojea-Jimenez, Victor Puntes. JACS-2009.


Project: "Nanoparticle based research to treat facial melasma".

Participant: Endor Technologies S.L.
Financed: ACCIO.
Year: 2014.

Project: "Development and clinical validation of a nanoparticle based delivery system for oncological drugs".

Participant: Endor Technologies S.L.
Financed: Centro de Desarrollo Tecnológico Industrial (CDTI).
Year: 2011.

Project: "Sustainable Hydrothermal Manufacturing of Nanomaterials (SHYMAN)".

Participants: Endor Technologies S.L., Nottingham University, Universidad de Valladolid, Instytut Wysokich Cisnien, Delft University, Trinity College Dublin, GTVP, Promethean Particles, Centro Ricerche FIAT, Akzo Nobel, Repsol, Solvay, Topgan, Itaprochim, Lewar GmbH, Boots UK, Van Loon Chemical Innovations, Pielaszek Research, Ceramysis.
Financed: Comisión Europea, Séptimo Programa Marco.
Year: 2011.

Project: "Nanosost: Towards a safe and responsible nanotechnology".

Participants: Endor Technologies S.L., Ceretox, Instituto Carlos III, Leia, Inasmet, Solutex.
Financed: Ministerio de Ciencia e Innovación.
Year: 2008.

Project: "Nanoheating sources for dermatological applications".

Participants: Endor Technologies S.L., Instituto de Ciencias Fotónicas (ICFO).
Financed: ACCIO.
Year: 2008.

Project: "Advanced nanomaterials synthesis for medical applications: ferromagnetic structures and multiple conjugation"

Participant: Endor Technologies S.L.
Financed: Centro de Desarrollo Tecnológico Industrial (CDTI).
Year: 2007.

Project: "Synthesis of advanced nanoparticles for its use in nanomedicine: Gold-Cobald core-shell structures".

Participants: Endor Technologies S.L., Instituto Catalán de Nanotecnología.
Financed: Ministerio de Industria, Energía y Turismo.
Year: 2007.